ANI Has Four-Pillar Growth Strategy Following Novitium Deal
As Company Sees Q4 Revenue Increase On The Back Of Generics Sales
With a four-pillar growth strategy, ANI Pharma plans over 25 product launches in 2021 and 2022. With the recent acquisition of Novitium the company is also advancing three 505(b)(2) candidates in oncology and hypertension, after seeing a slight growth in overall revenues and generics sales in 2020.
